393 related articles for article (PubMed ID: 17931529)
1. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
3. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
4. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
11. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
13. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Kaló Z
BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
17. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
Kim JJ; Goldie SJ
BMJ; 2009 Oct; 339():b3884. PubMed ID: 19815582
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
